Indivior Pharmaceuticals declared an $8.13-per-share special dividend, payable to eligible holders if its Merger with Supernus closes. The dividend matters to investors because payment depends on transaction approval and completion, with holders of record on October 30 expected to receive payment around November 6 if closing occurs as anticipated.

Key Highlights

  • Indivior set October 30 as the Record Date for eligible common-stock holders.
  • Equity award holders can receive $8.13 per underlying share upon vesting.
  • Payment is expected around November 6 if the merger closes as anticipated.

Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) declared a special Cash Dividend of $8.13 per share, with payment tied to completion of its merger with Supernus Pharmaceuticals. The distribution is intended for eligible Indivior shareholders and certain holders of Equity awards, but it remains conditional on the transaction closing.

$8.13 Dividend Sets October Record Date Shareholders recorded as owners of

Indivior common stock on October 30 will qualify for the cash payment. The same $8.13 per underlying share applies to certain equity awards outstanding on that date, although those amounts become payable to award holders when the awards vest. Indivior expects the Supernus merger to close on or around November 2. Payment to eligible record-date shareholders is anticipated around November 6 if that closing occurs.

Merger Conditions Govern Dividend Payment Merger Sub is expected to combine with

Supernus, which would remain in place as a wholly owned Indivior subsidiary. Supernus stockholders would not receive the Special Dividend on Indivior common stock issued as merger consideration. For U.S. holders, those amounts would generally be treated first as a return of Capital up to the holder’s basis and then as capital gain, according to the stated tax treatment.